Connor, Clark & Lunn Investment Management (CC&L)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-9,611	Closed	-$803K	–	1642
2024 Q4	$803K	Sell	9,611 -7,488	-44%	-$615K	﹤0.01%	1013
2024 Q3	$1.25M	Buy	+17,099	New	+$1.29M	0.01%	811
2023 Q4	–	Sell	-26,161	Closed	-$1.36M	–	1598
2023 Q3	$1.36M	Sell	26,161 -10,734	-29%	-$625K	0.01%	725
2023 Q2	$2.34M	Buy	36,895 +1,139	+3%	+$71K	0.01%	571
2023 Q1	$1.94M	Buy	35,756 +18,159	+103%	+$878K	0.01%	560
2022 Q4	$931K	Buy	17,597 +6,572	+60%	+$329K	0.01%	724
2022 Q3	$513K	Buy	11,025 +772	+8%	+$40.3K	﹤0.01%	813
2022 Q2	$585K	Buy	+10,253	New	+$581K	﹤0.01%	741
2019 Q4	–	Sell	-26,556	Closed	-$198K	–	1121
2019 Q3	$198K	Buy	+26,556	New	+$255K	﹤0.01%	867
2018 Q1	–	Sell	-11,425	Closed	-$165K	–	824
2017 Q4	$165K	Buy	+11,425	New	+$176K	﹤0.01%	732

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ITCI Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 9,611 shares — an estimated $803K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ITCI in Q4 2017 and held it in 10 quarters. The position peaked at $2.34M in Q2 2023. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 9,611 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $803K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Intra-Cellular Therapies Inc. in Q4 2017 and held it in 10 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Intra-Cellular Therapies Inc. position peaked at $2.34M in Q2 2023.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.